The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Sartorius Stedim Biotech's Revenue for the
three
months ended in Mar. 2026 was €762 Mil. Sartorius Stedim Biotech's average Accounts Receivable for the
three
months ended in Mar. 2026 was €220 Mil.
Hence, Sartorius Stedim Biotech's Receivables Turnover for the
three
months ended in Mar. 2026 was 3.46.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Sartorius Stedim Biotech Receivables Turnover Related Terms
Sartorius Stedim Biotech Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Sartorius Stedim Biotech's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DIMP vs ISRG, BDX, MDLN: Receivables Turnover Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech (CHIX:DIMP) has a Receivables Turnover of 3.46 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Sartorius Stedim Biotech and its competitors. According to the industry distribution chart, Sartorius Stedim Biotech ranks #65 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 8%.
Is Sartorius Stedim Biotech's Receivables Turnover too high?
Sartorius Stedim Biotech's current Receivables Turnover is 3.46. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Sartorius Stedim Biotech's value of 3.46 is 37.2% below this industry median. Based on the distribution chart, Sartorius Stedim Biotech ranks #65 out of 813 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sartorius Stedim Biotech has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Receivables Turnover compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #65 out of 813 companies for Receivables Turnover. This places Sartorius Stedim Biotech in the top 8% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.51. Sartorius Stedim Biotech's value of 3.46 is 37.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current Receivables Turnover of 3.46 is 37.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Sartorius Stedim Biotech and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current Receivables Turnover is 3.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Modestly Undervalued. The stock's GF Value™ is €207.96, compared to a current price of €179.05 — trading 13.9% below its estimated fair value. The current Receivables Turnover is 3.46 and 37.2% below the Medical Devices & Instruments industry median of 5.51. Sartorius Stedim Biotech's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current Receivables Turnover is 3.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of €179.05 is trading 13.9% below its estimated GF Value™ of €207.96.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for CHIX:DIMP:
Receivables Turnover: 3.46
GF Value™: €207.96 vs. price of €179.05 (13.9% below fair value)
Industry Position: 37.2% below the Medical Devices & Instruments median (#65 of 813)
No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
84GF Score
Get the complete analysis for CHIX:DIMP
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIMP has been successfully added to your 
